{'fraction_non_alphanumeric': 0.033660589060308554, 'fraction_numerical': 0.002805049088359046, 'mean_word_length': 5.5504587155963305, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 1, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Epigallocatechin‐3‐Gallate suppresses early stage, but not late stage prostate cancer in TRAMP mice: Mechanisms of action

Prostate cancer (PCa) is the second leading cause of cancer‐related death in men in the United States. Many men have implemented purported chemopreventive agents into their daily diet in an attempt to delay the early onset of a PCa. Green tea polyphenols, one such agent, has been shown to be chemopreventive in skin, breast, and prostate cancers. We hypothesized that Epigallocatechin‐3‐Gallate (EGCG), the major polyphenol found in green tea, will exert its chemopreventive effect in the prostate via regulation of sex steroid receptor, growth factor‐signaling, and inflammatory pathways.